SMC initial assessment of evidence for burosumab for X-linked hypophosphataemia with radiographic evidence of bone disease in children 1 year of age and older and adolescents

The SMC has advised that the Scottish Government Medicines Policy Branch will notify Health Boards when this medicine is available for prescribing within the ultra-orphan pathway. In the meantime, requests for treatment should be considered through local non-formulary processes.


Scottish Medicines Consortium